Huakang Biomedical Holdings Co (HKSE:08622) Total Current Assets : HK$58.43 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Huakang Biomedical Holdings Co's total current assets for the quarter that ended in Dec. 2024 was HK$58.43 Mil.

Huakang Biomedical Holdings Co Total Current Assets Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Total Current Assets Chart

Huakang Biomedical Holdings Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

69.95

65.71

59.66

58.45

58.43

Huakang Biomedical Holdings Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Total Current Assets	Get a 7-Day Free Trial															57.26	-	58.45	60.66	58.43

Huakang Biomedical Holdings Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Huakang Biomedical Holdings Co's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	38.965	+	13.089	+	2.901	+	3.471
	=	58.43

Huakang Biomedical Holdings Co's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	38.965	+	13.089	+	2.901	+	3.471
	=	58.43

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Huakang Biomedical Holdings Co (HKSE:08622) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Huakang Biomedical Holdings Co's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	38.965	-	11.93	+	0.75 * 10.622	+	0.5 * 2.901
=	36.45

Huakang Biomedical Holdings Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Huakang Biomedical Holdings Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Total Current Assets

Traded in Other Exchanges

N/A

Address

No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN

Website

http://www.szhuakang.com

Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.

Executives

Yu Chi Mau	2106 Person having a security interest in shares
Li King Yeung	2106 Person having a security interest in shares
Crystal Grant Limited	2101 Beneficial owner
Arena Investment Management (singapore) Pte Ltd	2102 Investment manager
Arena Investors, Lp	2102 Investment manager
Arena Sg Spv I, Llc	2201 Interest of corporation controlled by you
Tgga, Llc	2106 Person having a security interest in shares
Lau Lai Yee	2201 Interest of corporation controlled by you
Kokusai Resources Company Limited	2101 Beneficial owner
Zhang Shuguang	2101 Beneficial owner
Chang Yim Yang	2401 A concert party to an agreement to buy shares
Ever Charming Inc.	2101 Beneficial owner
Wealthy Pride Investment Limited	2101 Beneficial owner

Huakang Biomedical Holdings Co Headlines

No Headlines